🇺🇸 FDA
Pipeline program

MLN4924

C15009

Phase 1 small_molecule completed

Quick answer

MLN4924 for Acute Myelogenous Leukemia is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Acute Myelogenous Leukemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials